Can-Fite BioPharma Ltd. logo
Can-Fite BioPharma Ltd. CANF
$ 1.44 -1.37%
report update icon

Quarterly report 2022-Q4
added 11-18-2026

Can-Fite BioPharma Ltd. EPS Ratio | CANF

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.

Calculated as:

EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Can-Fite BioPharma Ltd.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-5.97 -10.9 -17.9 -0.01 -0.03 -0.04 -0.14 -0.17 - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-0.01 -17.9 -4.39

Quarterly EPS Ratio Can-Fite BioPharma Ltd.

2025-Q4 2025-Q2 2024-Q4 2024-Q2 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
-5.97 - -10.9 - -17.9 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
-5.97 -17.9 -11.6

References

  1. Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer EPS Ratio Price % 24h Market Cap Country
Champions Oncology Champions Oncology
CSBR
-0.08 $ 4.34 -1.36 % $ 60 M usaUSA
Mesoblast Limited Mesoblast Limited
MESO
-0.0846 $ 10.9 -2.5 % $ 13.2 B australiaAustralia
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
-0.47 $ 96.15 0.67 % $ 4.83 B usaUSA
MannKind Corporation MannKind Corporation
MNKD
0.02 $ 3.85 -2.66 % $ 1.18 B usaUSA
Dyadic International Dyadic International
DYAI
-0.23 $ 0.29 -6.53 % $ 10.5 M usaUSA
Merck & Co. Merck & Co.
MRK
7.3 $ 133.34 0.4 % $ 334 B usaUSA
Moderna Moderna
MRNA
-7.26 $ 195.25 -2.05 % $ 76 B usaUSA
NuCana plc NuCana plc
NCNA
-0.26 $ 0.75 4.39 % $ 8.42 B britainBritain
Novartis AG Novartis AG
NVS
7.21 $ 150.51 -0.47 % $ 292 B schweizSchweiz
Puma Biotechnology Puma Biotechnology
PBYI
0.62 $ 7.05 -1.05 % $ 353 M usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
-0.34 $ 3.69 -0.67 % $ 281 M usaUSA
PDS Biotechnology Corporation PDS Biotechnology Corporation
PDSB
-0.74 $ 0.79 -2.58 % $ 36.6 M usaUSA
Geron Corporation Geron Corporation
GERN
-0.13 $ 0.87 -4.76 % $ 580 M usaUSA
Pharming Group N.V. Pharming Group N.V.
PHAR
0.051 $ 11.54 -5.18 % $ 7.95 B niderlandNiderland
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
-3.03 $ 4.65 -8.46 % $ 339 M usaUSA
Genmab A/S Genmab A/S
GMAB
122 $ 50.36 -1.93 % $ 3.26 B danmarkDanmark
Gossamer Bio Gossamer Bio
GOSS
-0.75 $ 10.69 -4.81 % $ 2.44 B usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
0.23 $ 8.14 -0.73 % $ 5.53 B spainSpain
Liquidia Corporation Liquidia Corporation
LQDA
-0.8 $ 54.39 -3.96 % $ 4.68 B usaUSA
GlaxoSmithKline plc GlaxoSmithKline plc
GSK
1.41 $ 47.8 -0.05 % $ 194 B britainBritain
MediciNova MediciNova
MNOV
-0.24 $ 1.3 2.36 % $ 63.8 M usaUSA
PTC Therapeutics PTC Therapeutics
PTCT
8.58 $ 56.23 -3.59 % $ 4.47 B usaUSA
Pulmatrix Pulmatrix
PULM
-0.32 $ 1.24 -12.34 % $ 4.53 B usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
-0.68 $ 1.05 -3.67 % $ 70.7 M germanyGermany
Immunome Immunome
IMNM
-2.43 $ 15.69 -5.54 % $ 1.37 B usaUSA
Immuron Limited Immuron Limited
IMRN
-2.26 $ 0.9 5.87 % $ 208 M australiaAustralia
Incyte Corporation Incyte Corporation
INCY
6.59 $ 114.5 -1.19 % $ 22.4 B usaUSA
INmune Bio INmune Bio
INMB
-1.86 $ 0.82 -8.41 % $ 20.3 M usaUSA
Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Limited
RDY
67.9 $ 14.88 0.24 % $ 12.4 B indiaIndia
Regeneron Pharmaceuticals Regeneron Pharmaceuticals
REGN
43.1 $ 920.38 -0.22 % $ 96.3 B usaUSA
Ionis Pharmaceuticals Ionis Pharmaceuticals
IONS
-1.41 $ 26.58 -2.37 % $ 4.25 B usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
27 $ 1.06 -10.92 % $ 48.4 M israelIsrael
Ironwood Pharmaceuticals Ironwood Pharmaceuticals
IRWD
-0.01 $ 4.68 -0.53 % $ 757 M usaUSA
Kala Pharmaceuticals Kala Pharmaceuticals
KALA
-3.31 $ 2.73 -9.61 % $ 22.2 M usaUSA
Intellia Therapeutics Intellia Therapeutics
NTLA
-3.81 $ 10.02 5.24 % $ 1.09 B usaUSA
Adagene Adagene
ADAG
-0.3 $ 1.8 -10.56 % $ 106 M chinaChina
Denali Therapeutics Denali Therapeutics
DNLI
-2.97 $ 18.43 1.29 % $ 3.18 B usaUSA
Pfizer Pfizer
PFE
1.37 $ 27.4 -0.62 % $ 156 B usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
-0.09 $ 10.56 -6.26 % $ 4.38 B irlandaIrlanda
ImmuCell Corporation ImmuCell Corporation
ICCC
-0.12 $ 11.08 -0.81 % $ 100 M usaUSA
Editas Medicine Editas Medicine
EDIT
-1.8 $ 1.63 -4.68 % $ 145 M usaUSA
Kiniksa Pharmaceuticals, Ltd. Kiniksa Pharmaceuticals, Ltd.
KNSA
0.8 $ 93.83 0.32 % $ 6.96 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
-7.12 $ 27.54 -4.24 % $ 1.6 B usaUSA
Royalty Pharma plc Royalty Pharma plc
RPRX
1.79 $ 68.45 1.08 % $ 29.4 B usaUSA
Equillium Equillium
EQ
-0.39 $ 1.06 -5.36 % $ 60.7 M usaUSA
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
0.39 $ 1.32 -5.04 % $ 75.1 M usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
1.34 $ 2.42 -1.17 % $ 128 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
2.32 $ 17.1 -2.79 % $ 2.88 B usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
-4.04 $ 1.6 -8.86 % $ 13.8 M usaUSA